{
  "trial_id": "NCT03489473",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Primary or metastatic endometrial cancer",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Postmenopausal status",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "All histologic types of endometrial cancer",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Availability of recent (micro)curettage or biopsy",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Intercurrent treatment between biopsy taking and start of hormonal treatment",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Sarcoma of the uterus",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Contra-indications to perform a PET-CT scan or a CT scan with intravenous contrast",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "Use of hormonal therapy in the three months preceding performance of FES PET",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "45-year-old postmenopausal woman with cytologically confirmed breast cancer, HER2-positive and ER/PR negative.",
  "_meta": {
    "topic_id": "61",
    "trial_id": "NCT03489473",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}